Alnylam Pharmaceuticals, Inc. vs Pfizer, Inc. — Stock Comparison

ALNY
Alnylam Pharmaceuticals, Inc.
$296.11
▼ 4.32%
vs
PFE
Pfizer, Inc.
$26.33
▼ 1.39%
Q·Score Winner
Alnylam Pharmaceuticals, Inc.
ALNY8/10vs 6.5/10

Q·Score Breakdown

8
Bullish
Overall
6.5
Neutral
8.2
Quality
7.4
6.2
Health
7
8
Growth
5.6
9.7
Valuation
6.7
7.5
Sentiment
5.2
ALNY

Consensus analyst target of $449.48 is 52% above current price.

PFE

Strong profitability with 12% net profit margins.

analyst sentiment is cautious.

Analyst Consensus

BUY
Target $449.48 (+51.8%)
25 analysts
HOLD
Target $29.00 (+10.2%)
27 analysts

Fundamentals

ALNY
PFE
74.6×
Trailing P/E
19.4×
21.2×
Forward P/E
9.4×
12.6%
Profit Margin
12.4%
80.8%
Gross Margin
75.8%
90.4%
ROE
8.9%
96.4%
Revenue Growth
-1.2%
Earnings Growth
0.38
Beta
0.39
Price / Book
$39.5B
Market Cap
$149.8B
$246 – $496
52-Week Range
$22 – $29

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →